# WhiteLab Genomics

> TechBio company using AI to design delivery systems and genetic payloads for genomic medicines.

## Why it is interesting

The company is moving from computational services toward proprietary bio-assets, increasing licensing upside while accepting greater preclinical and development risk.

## Profile

- **Latest funding:** Series B — $26M (October 6, 2026)
- **Latest known valuation:** Undisclosed (October 6, 2026)
- **Total disclosed equity funding:** $26M
- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, ai-ml, healthtech
- **Coverage:** full
- **Last updated:** 2026-10-08T02:35:00Z
- **Latest funding investors:** AVP, Yaday Health, Blast Club, Omnes Capital, Debiopharm Innovation Fund

## Key facts

- Closed a $26M Series B led by AVP.
- Plans to fund preclinical validation and international expansion.

## Funding history

- Series B · $26M · October 6, 2026
  Source: https://whitelabgx.com/media-center/whitelab-genomics-raises-26-million-to-build-ai-designed-bio-assets-for-the-next-generation-genomic-medicines

## Investors in our directory

- https://venturecapitaltracker.com/fund/avp

## Related articles

- https://venturecapitaltracker.com/2026-namespace-clockwork-arboretum-200m-funding-roundup

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 8, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/whitelab-genomics